How to Submit to Lancet Oncology: Complete Guide

The editorial triage at Lancet Oncology is faster than at the parent Lancet but equally rigorous. Editors are asking three questions:

1. Does this change clinical oncology practice?

The paper needs to demonstrate that oncologists should do something differently based on this evidence. A biomarker study without treatment implications is cancer biology, not clinical oncology. A phase II trial without clear next steps for patient management is preliminary, not practice-changing.

2. Is the evidence level appropriate for the claim?

Lancet Oncology favors randomized controlled trials, large prospective cohort studies, and well-designed meta-analyses. Retrospective analyses and single-arm studies face a higher bar. The statistical design needs to be rigorous enough that the in-house statisticians won't find problems the authors missed.

3. Does the oncology community need this now?

Timeliness matters. A trial result in a treatment area with recent practice changes may be more urgent than a confirmatory study in a settled area. The editors think about what oncologists are debating right now.

This is where many Lancet Oncology submissions fail. The panel must include:

• Evidence before this study: What was known, with specific search strategy
• Added value of this study: What this paper specifically changes (not "adds to the literature")
• Implications of all the available evidence: How the totality of evidence, including this study, should change practice

A weak Research in Context panel reads like a condensed introduction. A strong one reads like a clinician explaining to a colleague why this study matters for their patients tomorrow.

The biology paper disguised as oncology. Strong mechanistic cancer research submitted to Lancet Oncology because of the prestige, but without clinical endpoints or patient-level evidence. These belong at Cancer Cell or Nature Cancer.

The underpowered trial. A phase II or single-arm study claiming practice-changing implications. Lancet Oncology's in-house statisticians will identify the limitations faster than most external reviewers.

The regional study without global relevance. A clinical finding relevant to one healthcare system but not generalizable. The Lancet regional journals (Lancet Regional Health) may be more appropriate.

The incremental survival improvement. A new treatment that extends median survival by weeks in a heavily treated population, without quality-of-life data or cost-effectiveness context. The editors want the full clinical picture.

Submit if:

• the study presents clinical evidence that could change oncology treatment guidelines
• the trial design is randomized or the observational evidence is exceptionally strong
• the Research in Context panel writes itself (the clinical implications are clear)
• the finding has global oncology relevance, not just regional significance

Think twice if:

• the paper is primarily cancer biology without clinical endpoints (Cancer Cell, Nature Cancer)
• the trial is early-phase without clear practice implications (JCO may be more appropriate)
• the clinical importance is real but specific to one cancer subtype (specialty journals may fit better)
• the statistical design has known limitations you haven't addressed

Before submitting, a free manuscript scan can assess whether the clinical framing and evidence strength meet Lancet Oncology's editorial threshold.

How selective is Lancet Oncology?

Very. Desk rejection is estimated at 70-80%. Overall acceptance rate is roughly 8-10%.

Does Lancet Oncology have in-house statisticians?

Yes, inherited from the Lancet family. Statistical review runs concurrently with peer review.

What's the difference between Lancet Oncology and JCO?

Lancet Oncology (IF 35.9) is more selective and emphasizes global practice change. JCO (IF 41.9) has a broader scope within clinical oncology and publishes more papers.

Can I submit translational oncology to Lancet Oncology?

Only if the translational finding has clear clinical implications with patient-level evidence. Pure translational work belongs at Science Translational Medicine or Cancer Discovery.